Neuroone Medical Technologies Corp
NASDAQ:NMTC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (21.8), the stock would be worth $-2.71 (158% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -37.8 | $4.7 |
0%
|
| Industry Average | 21.8 | $-2.71 |
-158%
|
| Country Average | 21.9 | $-2.72 |
-158%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
236.9m USD | -37.8 | -34.7 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
162.5B USD | 65.2 | 56.9 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
157.7B USD | 29.4 | 25.1 | |
| US |
|
Stryker Corp
NYSE:SYK
|
120.5B USD | 22.1 | 37.1 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.9B USD | 27.6 | 22.5 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
85.4B USD | 29.8 | 24 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.5B USD | 36.8 | 44.2 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
39.3B EUR | 41.4 | 18.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
44.7B USD | 45.5 | 42.2 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
42.4B USD | 17.6 | 24.2 | |
| US |
|
Resmed Inc
NYSE:RMD
|
31.1B USD | 17.9 | 21 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Neuroone Medical Technologies Corp
Glance View
NeuroOne Medical Technologies Corp. operates as a medical technology company. The company is headquartered in Eden Prairie, Minnesota and currently employs 11 full-time employees. The company went IPO on 2012-11-09. The firm is focused on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, spinal cord stimulation, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders. The company also investigating the applications of its technology associated with artificial intelligence. The company develops its cortical, sheet and depth electrode technology to provides solutions for diagnosis through cEEG recording and sEEG recording and treatment through brain stimulation and ablation. Its commercialized product, Evo sEEG electrode technology records, monitors and stimulates electrical signals at the subsurface level of the brain.
